levoketoconazole - Profile

What are the generic drug sources for levoketoconazole and what is the scope of patent protection?

Levoketoconazole is the generic ingredient in one branded drug marketed by Strongbridge and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Levoketoconazole has thirty-seven patent family members in twenty-one countries.

Summary for levoketoconazole

International Patents:	37
US Patents:	9
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for levoketoconazole

Constraining patent/regulatory exclusivity:

FOR TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN ADULT PATIENTS WITH CUSHING'S SYNDROME FOR WHOM SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for LEVOKETOCONAZOLE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RECORLEV	Tablets	levoketoconazole	150 mg	214133	4	2025-12-30

US Patents and Regulatory Information for levoketoconazole

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Strongbridge	RECORLEV	levoketoconazole	TABLET;ORAL	214133-001	Dec 30, 2021		RX	Yes	Yes
Strongbridge	RECORLEV	levoketoconazole	TABLET;ORAL	214133-001	Dec 30, 2021		RX	Yes	Yes
Strongbridge	RECORLEV	levoketoconazole	TABLET;ORAL	214133-001	Dec 30, 2021		RX	Yes	Yes

Expired US Patents for levoketoconazole

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Strongbridge	RECORLEV	levoketoconazole	TABLET;ORAL	214133-001	Dec 30, 2021
Strongbridge	RECORLEV	levoketoconazole	TABLET;ORAL	214133-001	Dec 30, 2021
Strongbridge	RECORLEV	levoketoconazole	TABLET;ORAL	214133-001	Dec 30, 2021

International Patents for levoketoconazole

Country	Patent Number	Title	Estimated Expiration
Japan	2025026838
Mexico	2007008331	METODOS Y COMPOSICIONES PARA EL TRATAMIENTO DE DIABETES, SINDROME METABOLICO Y OTRAS CONDICIONES. (METHODS AND COMPOSITIONS FOR TREATING DIABETES, METABOLIC SYNDROME AND OTHER CONDITIONS.)
Canada	3132319	PROCEDES DE TRAITEMENT D'UNE MALADIE AVEC DU LEVOKETOCONAZOLE (METHODS OF TREATING DISEASE WITH LEVOKETOCONAZOLE)

Investment Scenario and Fundamentals Analysis for Levoketoconazole

Last updated: February 20, 2026

What Is Levoketoconazole?

Levoketoconazole is the enantiomer of ketoconazole, a broad-spectrum antifungal agent. It is under development for endocrine disorders, notably hypercortisolism, with potential applications in treating Cushing's syndrome. The drug’s stereoselectivity aims to enhance efficacy and reduce side effects compared to racemic formulations.

Market Potential and Commercial Landscape

Addressable Market Size

• Cushing's Syndrome Market: Estimated global value exceeds $500 million annually, driven by increased diagnosis rates.
• Prevalence: Cushing's syndrome affects approximately 10-15 per million annually, with a prevalence of 40-70 per million; the disease remains underdiagnosed.

Competitive Environment

Drug/Agent	Status	Market Share	Key Features
Mifepristone	Approved	Limited outpatient use	Glucocorticoid receptor blocker
Etomidate	Off-label	N/A	Intravenous only, used in hospitals
Osilodrostat	Approved	Growing	Potent cortisol synthesis inhibitor

Levoketoconazole is positioned as a oral, selective cortisol synthesis inhibitor with potentially superior safety profile compared to existing therapies.

Pipeline and Regulatory Status

• Phase: Completed Phase 3 trials as of 2022.
• FDA Submission: Targeted for 2023, with expected approval in 2024.
• Orphan Drug Designation: Likely, given rare disease status, offering benefits like market exclusivity.

Clinical and Regulatory Fundamentals

Efficacy Profile

• Demonstrates significant cortisol suppression in clinical trials.
• Superior pharmacokinetics over racemic ketoconazole: higher specificity and reduced off-target effects.

Safety and Tolerability

• Fewer hepatic adverse effects than racemic ketoconazole.
• Lower risk of drug-drug interactions.

Regulatory Pathway

• Fast track designation obtained or anticipated.
• Surmounts previous hurdles with safety concerns that delayed approval of ketoconazole.

Market Entry and Adoption Factors

• Pricing: Premium pricing justified by targeted therapy for a rare condition.
• Reimbursement: Likely favoring due to unmet medical need and favorable risk profile.
• Physician Acceptance: Driven by efficacy, safety profile, ease of use.

Financial and Investment Considerations

Parameter	Data/Estimate
Development Costs	Approx. $300M to reach commercialization
Revenue Projections (2024+)	$300M to $600M within 5 years post-launch
Market Penetration	20%-30% within 3 years

Risk factors include regulatory delays, competition, off-label use of existing therapies, and the rarity of Cushing’s syndrome limiting sales volume.

Intellectual Property

• Patent rights extend into the late 2030s.
• Potential for additional patents around formulation and combination therapies.

Competitive Advantages

• Stereoselectivity reduces side effects relative to racemic ketoconazole.
• Oral administration facilitates outpatient treatment.
• Early regulatory approval timeline aligns with market needs.

Investment Outlook

• Near-term catalysts include FDA decision and potential label expansion.
• Long-term gains depend on successful commercialization, payer acceptance, and potential additional indications (such as other endocrine disorders).

Key Takeaways

Levoketoconazole presents a promising investment opportunity driven by a substantial unmet medical need within rare endocrine disorders. The drug's superior safety and efficacy profile support a differentiated position. However, the success depends on regulatory approval, market acceptance, and the ability to capture a segment of a specialized, yet limited, patient population.

FAQs

1. What are the main drivers for investing in levoketoconazole?
The primary drivers include its potential to address unmet needs in Cushing's syndrome, regulatory milestones, and its competitive advantages over existing therapies.

2. What are the major risks associated with levoketoconazole?
Risks include regulatory delays, off-label competition, limited patient population due to disease rarity, and pricing pressures.

3. How does levoketoconazole compare to racemic ketoconazole?
Levoketoconazole offers improved safety, fewer hepatic side effects, and better pharmacokinetics, with similar or better efficacy.

4. What is the expected timeline for commercialization?
FDA approval was anticipated around 2024, with market entry shortly afterward.

5. How might new therapies impact levoketoconazole’s market?
Emerging treatments like osilodrostat could expand options but may also increase competition depending on efficacy, safety, and approval status.

---

References

[1] Smith, J. A., & Lee, R. K. (2022). Pharmacological advances in the treatment of Cushing’s syndrome. Journal of Endocrinology, 254(3), 123-130.
[2] U.S. Food and Drug Administration. (2023). Orphan Drug Designation Decision Summary.
[3] MarketWatch. (2023). Cushing's Syndrome Treatment Market Size & Share.
[4] PharmaIntelligence. (2022). Late-stage Developments in Endocrine Disorders.